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Abstract
Background: Dupuytren’s contracture is a condition of the palmar fascia involving contractures of the fascia and skin
in the hand. Current treatment for Dupuytren’s contracture is mainly limited to surgery. In the Netherlands, little is
known about the prevalence of Dupuytren’s contracture. In this study we determined the prevalence of patients with
a hospitalization for Dupuytren’s contracture in the Netherlands and characterized their (re)hospitalizations.
Methods: From the PHARMO database, which consists of multiple observational databases linked on a patient level, all
patients hospitalized for Dupuytren’s contracture between 2004 and 2007 were included in the source population (ICD-
9-CM code 728.6). Numbers from this source population were used to provide estimates of hospitalizations for
Dupuytren’s contracture in the Netherlands. Patients with a medical history in the PHARMO database of at least 12
months before their hospitalization were included in the study cohort and followed until end of data collection, death,
or end of study period, whichever occurred first. Type of admission, length of stay, recorded procedures, treating
specialty, number of rehospitalizations for Dupuytren’s contracture, and time to first rehospitalization were assessed.
Results: Of 3, 126 patients included in the source population, 3, 040 were included in the study population. The
overall prevalence of patients with a hospitalization for Dupuytren’s contracture was 0.04%, with the highest
prevalence (0.25%) among 60-79 year old males. The majority (85%) of all hospitalizations were day-case
admissions. Of the admitted inpatients (15%) the majority (81%) had one overnight stay in the hospital. The most
common recorded procedure was fasciectomy (87%) and 78% of patients was treated by a plastic surgeon. During
a median (IQR) follow-up of 2.9 (1.8-4.0) years, 523 patients were rehospitalized for Dupuytren’s contracture. The
median (IQR) time to first rehospitalization was 0.8 (0.4-1.9) years.
Conclusions: This study is a first exploration of Dupuytren’s contracture in the Netherlands based on
hospitalizations, showing a prevalence of 0.25% among 60-79 year old males. Future studies should also address
outpatient procedures to get a complete picture of the treatment of Dupuytren’s contracture. In addition, patients
not yet treated should be included to be able to estimate the prevalence of Dupuytren’s contracture.
Background
Dupuytren’s contracture is a slowly progressing, usually
painless condition of the palmar fascia involving contrac-
tures of the fascia and skin in the hand [1]. The diagnosis
is based on the presence of fibromatous nodule forma-
tions in the palmar fascia, which slowly (i.e. over several
months or even years) progress to cords leading
eventually to contractures of joints in fingers. The condi-
tion most commonly affects the ring and little fingers,
although any digit can be involved. The main conse-
quence of Dupuytren’s contracture is impaired function
of the hand, which affects daily activities at the workplace
and at home [1].
Little is known about the prevalence of Dupuytren’s
contracture in the Netherlands [2]. Several epidemiologic
studies in other European countries mention a prevalence
that varies widely from 4 to 11 percent, with highest rates
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in Northern European countries [3]. This geographic
variability may be due to a genetic element, environmental
factor, or a combination of the two [3]. Furthermore, pre-
valence of Dupuytren’s contracture is highest among older
men [4-6]. Although many studies have been performed,
the exact etiology of Dupuytren’s contracture remains
unknown. Evidence suggests an autosomal dominant pat-
tern of inheritance with incomplete penetrance [7]. Most
commonly mentioned risk factors for Dupuytren’s con-
tracture are diabetes mellitus, epilepsy, smoking, alcohol
consumption, and manual labor, however, not all studies
support these findings [4-6,8,9]. Some studies also suggest
that a lipid disorder may be an etiopathogenic factor for
Dupuytren’s contracture [10,11].
Disease progression is classified using a grading system.
Grade 1 disease presents as a thickened nodule and a
band in the palmar apononeurosis. Grade 2 presents as a
peritendinous band, and extension of the affected finger
is limited. Grade 3 presents as flexion contracture [1,11].
Grade 1 disease initially can be managed expectantly, but
injecting the nodule with a steroid can be helpful. Sur-
gery is recommended if function is impaired, contracture
is progressing, or severe deformity is disabling. Surgery
includes removing (-ectomy) or releasing (-otomy) the
fibrotic cord to allow extension of the affected finger(s)
and restoration of hand function. Surgical techniques
available include fasciotomy, fasciectomy (radical or par-
tial), dermatofasciectomy, and percutaneous needle fas-
ciotomy or aponeurotomy [12]. Two studies report a
proportion of 7% of patients with Dupuytren’s contrac-
ture that received surgical treatment; no information was
available on type of surgical treatment [4,5]. After sur-
gery, most patients can expect a significant improvement
in hand function [11]. However, surgery does not cure
the disease and recurrences are commonly observed [13].
Recurrence rates are dependent on the applied surgical
procedure, ranging from 8% after 6 years for dermatofas-
ciectomy to 65% after 32 months for percutaneous needle
fasciotomy [12].
Because of lacking data on Dupuytren’s contracture in
the Netherlands, the aim of this study was to determine
prevalence of patients with a hospitalization for Dupuyt-
ren’s contracture in the Netherlands and to characterize
their (re)hospitalizations. This study will include more
severe cases, because surgery (i.e. hospitalizations) is




Data for this retrospective cohort study were obtained
from the PHARMO Record Linkage System (PHARMO
RLS), a population-based patient centric data tracking
system including high quality and complete information
linked on a patient level of, among other things, patient
demographics, drug dispensing records from community
pharmacies and hospital discharge records of approxi-
mately 2.5 million individuals from 1998 and still
ongoing in defined areas throughout the Netherlands.
The hospital records are obtained from the Dutch
National Medical Register (LMR) [14], which comprises
all hospital admissions in the Netherlands, i.e. admissions
for more than 24 hours and admissions for less than 24
hours for which a bed is required. These records include
detailed information concerning the primary diagnosis,
procedures, and dates of hospital admission and dis-
charge. All diagnoses are coded according to the Interna-
tional Classification of Diseases, Ninth Revision, Clinical
Modification (ICD-9-CM). Procedures are coded accord-
ing to the Dutch classification of procedures ("CvV -
Classificatie van Verrichtingen”). No approval was
required to access the databases, because the study was
performed by employees of the PHARMO Institute
(owner of the PHARMO RLS).
Study patients
The source population included all patients with a primary
hospital admission for Dupuytren’s contracture (ICD-9-
CM code 728.6) between January 1, 2004 and December
31, 2007. The date of the first primary hospital admission
for Dupuytren’s contracture in this study period was
defined as the cohort entry date; consequently the source
population included patients with a first hospitalization for
Dupuytren’s contracture, but also patients with previous
hospitalizations for Dupuytren’s contracture. Patients were
included in the study cohort if they had a history of at
least 12 months in PHARMO RLS before cohort entry
date, in order to determine their co-morbidities and co-
medication at the time of the first known hospitalization
in the study period. Patients were followed from cohort
entry date to end of data collection in the PHARMO RLS
(i.e. the patient moves out of the PHARMO RLS catch-
ment area), death, or end of the study period (December
31, 2008), whichever occurred first.
Prevalence
The yearly number of patients with a hospitalization for
Dupuytren’s contracture in the Netherlands between Janu-
ary 1, 2004 and December 31, 2007 was estimated by extra-
polating the numbers derived from the source population,
standardized for age and gender [15]. Numbers are given
per 100, 000 inhabitants, rounded off to 5, stratified by gen-
der and age, and include 95% confidence intervals (CI).
Characteristics
For all study patients the following characteristics were
determined at cohort entry date: gender, age, and co-
morbidities/co-medication based on hospitalizations
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and/or drug use in the year prior to cohort entry date
including diabetes mellitus (ICD-9-CM code 250 and/or
use of antidiabetics), epilepsy (ICD-9-CM code 345 and/
or use of antiepileptics), and use of lipid modifying
agents. In addition, the following characteristics of the
hospitalization at cohort entry date were determined:
type of admission (day-case or inpatient), length of stay,
recorded type of procedures (fasciotomy ("CvV"-proce-
dure codes 5-820.2 and/or 5-821.2), fasciectomy ("CvV"-
procedure codes 5-823.5 and not 5-884.2, 5-892, 5-893,
5-895, or 5-896 (skin related procedures) during same
hospitalization), and dermatofasciectomy ("CvV"-proce-
dure code 5-823.5 and 5-884.2, 5-892, 5-893, 5-895, or
5-896 (skin related procedures) during same hospitaliza-
tion)), and treating specialty.
Rehospitalizations
Rehospitalizations for Dupuytren’s contracture (primary
discharge diagnosis ICD-9-CM code 728.6) were assessed
in the period between cohort entry date and end of fol-
low-up. The number of rehospitalizations was determined,
as was the time to first rehospitalization and the treating
specialty during the first rehospitalization.
Statistical analysis
The 95% CI around the prevalence of patients with a hos-
pitalization for Dupuytren’s contracture (N per 100, 000)
was calculated using the formula N ± 2*√N [16]. Charac-
teristics of patients with a hospitalization for Dupuytren’s
contracture were presented descriptively. As the latest data
on national trends in hospitalization show that lengths of
hospital stays are declining, a Cochran-Armitage test for
trend [17] was used to assess whether the proportion of
day-case admissions changed in a specific direction over
time.
Survival functions describing the proportion and 95% CI
of patients without a rehospitalization for Dupuytren’s
contracture over time were computed using Kaplan-Meier
survival analyses censoring patients who were considered
lost to follow-up [18].
Data management and analyses were conducted using
SAS version 9.1 within SAS Enterprise Guide version
4.0 (SAS Institute Inc., Cary, NC, USA).
Results
The source population included 3, 126 patients with a
primary hospital admission for Dupuytren’s contracture
between January 1, 2004 and December 31, 2007. Preva-
lence estimates of patients hospitalized for Dupuytren’s
contracture are shown in Table 1. After extrapolating the
number of patients from PHARMO RLS to the entire
population of Netherlands, we determined that each year
about 40 patients per 100, 000 inhabitants were hospita-
lized for Dupuytren’s contracture. The highest prevalence
was among males 60-79 years of age: approximately 250
hospitalized per 100, 000 males each year.
A total of 3, 040 patients (97%) had a history of at least 12
months in PHARMO RLS and were included in the study
population (Figure 1). Of these patients, 76% were male
and the mean (± SD) age was 62 (± 12) years (Table 2).
Diabetes mellitus and epilepsy were present in 11% and 2%
of the patients, respectively and 22% of the patients used
lipid modifying agents.
Eighty five percent (85%) of the hospitalizations were
day-case admissions, this proportion increased from 82%
in 2004 to 92% in 2007 (p < 0.0001). Among patients
with an inpatient admission (15%, n = 449), 81% had
one overnight stay in the hospital. The most common
recorded procedure was fasciectomy (87%) and 78% of
patients was treated by a plastic surgeon.
During a mean (± SD) follow-up of 2.9 (± 1.4) years,
523 patients had a rehospitalization for Dupuytren’s con-
tracture. After a period of 4 years, the proportion of
patients without a rehospitalization for Dupuytren’s con-
tracture was 78% (95% CI: 76%-78%), resulting in 22%
(95% CI: 20%-24%) of patients with a rehospitalization
for Dupuytren’s contracture (Figure 2). Of all patients
with a rehospitalization, 85% had 1 rehospitalization
(median (IQR) follow-up: 3.2 (2.1-4.2) years), 13% had 2
rehospitalizations (median (IQR) follow-up: 3.6 (2.8-4.4)
years), and 2% had 3 or more rehospitalizations (median
(IQR) follow-up: 4.1 (3.5-4.8) years). Overall, the median
(IQR) time to first rehospitalization was 0.8 (0.4-1.9)
years. The type of treating specialist during rehospitaliza-
tions was nearly always (94%) identical to that during
initial hospitalization at cohort entry date.
Discussion
In this population-based study the prevalence of patients
with a hospitalization for Dupuytren’s contracture in the
Netherlands was estimated at 0.04%. The highest preva-
lence of 0.25% was among men 60-79 years of age, which
is comparable to the general finding that Dupuytren’s
contracture is known to mainly affect middle-aged and
elderly males [4-6].
Prevalence rates were based on hospitalization dis-
charge records in the PHARMO RLS, which is represen-
tative of the Netherlands. These records include a single,
mandatory primary diagnose code and may include one
or more optional secondary diagnose codes. As the latter
may relate to a concurrent diagnosis during hospitaliza-
tion as well as to a relevant diagnosis from the past, we
only selected patients with a primary diagnose code for
Dupuytren’s contracture. Consequently, some hospitali-
zations for Dupuytren’s contracture were missed, but this
is expected to concern only a very small number.
Furthermore, it is important to realize that the observed
rates of hospitalizations for Dupuytren’s contracture do
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not represent the rates of treatment for Dupuytren’s con-
tracture, as procedures performed during an outpatient
visit, presumably mostly percutaneous needle fasciotomy,
were not included. Outpatient visits do not require
admission and are not registered in the PHARMO
database.
Our prevalence estimate was lower compared to other
European studies. In the Reykjavik study, a population-
based prospective cohort study [4], 19% of 1, 297 men ≥45
years of age showed signs of Dupuytren’s contracture and
1.4% of them had been operated for Dupuytren’s contrac-
ture. Zerajic and Finsen [5] examined hands of 610 males
and 597 females ≥50 years of age in Bosnia and Herzego-
vina and 2.6% of males and 1.2% of females stated that
they had been operated for Dupuytren’s contracture.
Although not clearly stated by the authors, we assume this
included procedures during hospital admissions as well as
outpatient procedures.
Table 1 Prevalence of patients with a hospitalization for Dupuytren’s contracture in the Netherlands between 2004
and 2007
Number of patients per 100, 000 inhabitants (95% CI)
2004 2005 2006 2007
Total (males + females) 35 (35-40) 45 (40-45) 40 (40-45) 40 (40-45)
Males
0-59 years 30 (25-30) 30 (30-35) 30 (25-35) 30 (25-35)
60-79 years 230 (205-255) 260 (235-285) 255 (230-280) 245 (220-270)
≥80 years 110 (65-155) 125 (75-175) 115 (65-160) 105 (65-140)
Females
0-59 years 5 (5-10) 5 (5-10) 5 (5-10) 10 (5-10)
60-79 years 55 (45-65) 70 (60-85) 70 (60-85) 65 (55-80)
≥80 years 25 (15-40) 35 (15-50) 35 (20-50) 30 (15-40)
CI = confidence interval
Figure 1 Flowchart of selection of patients with hospitalization for Dupuytren’s contracture.
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Partial fasciectomy is the most widely used procedure
for the management of Dupuytren’s contracture
[12,19,20]. In our study, for 87% of patients hospitalized
for Dupuytren’s contracture a fasciectomy was recorded,
which corresponds to a database study in the UK [21].
An important remark regarding this result is that, in the
Netherlands, similar to the situation regarding discharge
diagnoses described above, physicians are obligated to
register one procedure, i.e. the primary procedure, but
not necessarily all procedures performed. This would
imply that the number of procedures used to manage
Dupuytren’s contracture may be incomplete and under-
estimated, but given that the extent of this misclassifica-
tion is expected to be small or inconsequential, the
degree of underestimation is also expected to be small
or inconsequential. Furthermore, dermatofasciectomy,
which includes two procedures, may have been slightly
underestimated as well.
Surprisingly, for about 9% of patients no procedure
was recorded during their admission for Dupuytren’s
contracture; unfortunately, there is no explanation for
this finding.
Regarding the co-morbidities potentially increasing the
risk of Dupuytren’s contracture, we found that 11% of
the study patients had diabetes, 2% had epilepsy, and 22%
used lipid modifying agents. In the absence of an age and
sex matched control group, we cannot judge whether
these proportions are high. In the general Dutch popula-
tion 4% has diabetes mellitus [22], 1% epilepsy [23], and
9% use lipid modifying agents [24]. However, this con-
cerns a population with a lower mean age and a higher
proportion of women, therefore it is difficult to assess
Table 2 Characteristics of patients with a hospitalization for Dupuytren’s contracture
Total*
N = 3, 040
n (%)
Gender
Male 2, 297 (76)
Female 743 (24)
Age (years)
0-19 15 (< 0.5)
20-44 191 (6)
45-59 925 (30)
60-69 1, 043 (34)
70-79 718 (24)
≥80 148 (5)
mean ± SD 62 ± 12
Co-morbidities/co-medication**
Diabetes Mellitus 323 (11)
Epilepsy 59 (2)
Use of lipid modifying agents 683 (22)
Type of admission
Day-case 2, 591 (85)
Inpatient 449 (15)
Procedures for Dupuytren’s contracture
Fasciotomy 32 (1)
Fasciectomy 2, 634 (87)
Dermatofasciectomy 49 (2)
Combination of fasciotomy, fasciectomy, and/or dermatofasciectomy 2 (< 0.5)
Other procedure for Dupuytren’s contracture† 44 (1)
No procedure 279 (9)
Surgical specialty
General surgeon 518 (17)
Plastic surgeon 2, 362 (78)
Orthopedic surgeon 156 (5)
Other specialty 4 (< 0.5)
SD = standard deviation; *Number of patients with a hospitalization for Dupuytren’s contracture in January 1, 2004 and December 31, 2007; **Based on
hospitalization(s) and/or drug use in the year prior to cohort entry date; †Most observed procedures were tenotomy (n = 7), tenectomy (n = 6), and tenolyse (n = 5)
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whether the prevalence of these co-morbidities is indeed
increased among patients with Dupuytren’s contracture.
In our study the percentage of day-case versus inpati-
ent admissions increased significantly over time, which
is comparable to the increase reported by Gerber et al.
[21]. The increase in our study might be explained by
the growing popularity of percutaneous needle fasciot-
omy in the last years. This minimally invasive treatment
with good short-term results is likely to be performed
during a day-case admission.
After a period of 4 years, about one-fifth (22%) of the
patients had a rehospitalization for Dupuytren’s contrac-
ture. It was not possible to label rehospitalizations as
recurrences, because we do not know whether this con-
cerned the same hand or finger as the hospitalization at
cohort entry date. Between 2004 and 2007, Gerber et al.
[21] found that about 20% of the patients had two or
more hospital admissions for Dupuytren’s contracture
within one year. The recurrence rate after fasciectomy is
about 41% after 5 years [12].
This study was limited to hospitalizations for Dupuyt-
ren’s contracture and should be considered as a first
exploration of Dupuytren’s contracture in the Nether-
lands. Future studies should also address outpatient pro-
cedures to get a complete picture of the treatment of
Dupuytren’s contracture. In addition, patients not yet
treated should be included to be able to estimate the
prevalence of Dupuytren’s contracture.
Conclusions
In conclusion, the prevalence of patients with a hospita-
lization for Dupuytren’s contracture was 0.04%, with the
highest prevalence (0.25%) among 60-79 year old males.
About one-fifth of patients had a rehospitalization
Figure 2 Proportion of study patients without a rehospitalization for Dupuytren’s contracture over time. NOTE: Incomplete follow-up
was censored due to loss of follow-up in the PHARMO RLS or due to death.
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within 4 years. Estimates of the prevalence and treat-
ment of Dupuytren’s contracture in the Netherlands will
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